The FDA has approved Keytruda plus chemotherapy in HER2+ gastric or GEJ adenocarcinoma with PD-L1–positive expression, based on KEYNOTE-811 data.

The US Food and Drug Administration (FDA) has granted traditional approval to Merck & Co’s (NYSE: MRK) Keytruda ...

The conversion from accelerated approval to traditional approval was supported by data from the phase 3 KEYNOTE-811 trial.

On March 19, the Food and Drug Administration granted traditional approval to pembrolizumab, or Keytruda, marketed by Merck (MRK), with ...

Summit Therapeutics (NASDAQ: SMMT) is one of those stocks that have been quite explosive: The share price of the ...

When combined with trastuzumab and chemotherapy, treatment with pembrolizumab was associated with a statistically significant improvement in PFS and OS compared with placebo. The conversion to ...

The Trial in Progress poster includes an overview and study design of the TACTI-004 Phase III evaluating the Company’s MHC Class II agonist, eftilagimod alfa (efti) in combination with MSD’s (Merck & ...

The trial evaluates Immutep’s MHC Class II agonist, eftilagimod alfa (efti), in combination with Merck’s KEYTRUDA® and chemotherapy for first-line treatment of advanced or metastatic non ...

PD-1 inhibitor Keytruda (pembrolizumab) given alongside chemotherapy reduced the risk of disease progression or death by 35% compared to chemo alone in the phase 3 KEYNOTE-355 trial, according to ...

Find out more about the overall breast cancer treatment landscape, as biotech companies make progress with different ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...